Specific targeting peptide CIBB composition capable of protecting ovarian injury caused by tumor and application of specific targeting peptide CIBB composition
By specifically targeting the peptide CIBB composition, the combination of CXCL10 and IL18R1 is prevented, and the problem of damage to ovarian function is solved by tumor treatment, and the effect of protecting ovarian function is achieved. It is suitable for the combined use with a variety of tumor treatment plans, ensuring the childbearing age Female reproductive health.
Patent Information
- Application Number
- CN202411004394.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-12-06
AI Technical Summary
Malignant tumor treatment, including radiotherapy and chemotherapy, can damage women's ovarian function. The impact of tumor immunotherapy on ovarian function is unclear, resulting in the possibility of subfertility or infertility in women with tumors.
Develop a specific targeted peptide CIBB composition that protects ovarian function by blocking the binding of CXCL10 to IL18R1 for use in combination with traditional tumor treatment regimens, including oral, infusion or intramuscular injection, and is highly specific, highly efficient, and low Immunogenicity and low cost.
It effectively protects the ovarian function of tumor women, avoids damage to the ovary by tumor treatment, does not interfere with the normal function of other inflammatory factors, and can be used in combination with a variety of tumor treatment plans to ensure the ovarian function and fertility of women of childbearing age.
Smart Images

Figure CN119074946A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of ovarian medical treatment, and specifically relates to a specific targeting peptide CIBB composition capable of protecting the ovarian from tumor damage and an application thereof. Background Art
[0002] It is known that the occurrence of malignant tumors itself can significantly reduce female ovarian function, and traditional radiotherapy and chemotherapy can also significantly damage the ovaries. Therefore, young female patients with malignant tumors may become subfertile or infertile even if they eventually overcome the tumor through various therapies. Tumor immunotherapy has recently become a promising new treatment for malignant tumors with high malignancy and lethality, but it is still unclear whether and how (positively or negatively) tumor immunotherapy affects female ovarian function. In this study, two popular immunotherapies, PD-1 monoclonal antibody (PD-1) therapy and whole cancer cell vaccine (WCV) therapy, were used as a model to investigate whether ovarian function was affected by two popular immunotherapies, PD-1 monoclonal antibody (PD-1) therapy and whole cancer cell vaccine (WCV) therapy. Mice treated with MCA205 (M) tumor cell ectopic transplantation showed a decrease in the number of follicles, decreased proliferation, increased apoptosis, and decreased oocyte maturation rate at each stage. WCV treatment significantly reversed these abnormalities, while PD-1 did not. RNA sequencing of ovaries showed that multiple differentially expressed genes (DEGs) were involved in inflammatory pathways. Furthermore, cytokine microarray analysis revealed that CXCL10 levels increased the most in the M group, and WCV treatment resulted in the best rescue of CXCL10 levels, while PD-1 antibody treatment had no significant effect. Next, CXCL10 antibody immunoprecipitation and LC-MS in ovarian lysates revealed that IL18R1 was the only receptor among the ovarian interacting proteins "captured" by CXCL10. Next, we found that CXCL10 could impair ovarian function through at least three pathways: inducing ovarian fibrosis through CXCL10→IL18R1→p-JNK→COL1A1; promoting primordial follicle overactivation through CXCL10→IL18R1→p-AKT; and increasing ovarian inflammation through CXCL10→IL18R1→p-P65. Finally, we rescued the decreased ovarian function in the M group mice by blocking the binding of CXCL10 to IL18R1 with CXCL10 antibody or CXCL10-IL18R1 interface peptide CIBB. This study provides mechanistic evidence and translational medicine strategies for WCV to achieve the dual functions of inhibiting tumor progression and protecting ovarian function. Summary of the invention
[0003] Technical problem to be solved: The present invention provides a specific targeting peptide CIBB composition and its application that can protect the ovarian damage caused by tumors. The peptide composition can protect the ovarian function of women with tumors from the damage caused by tumors. The scheme can be used in combination with a variety of tumor treatment schemes to ensure the ovarian function and fertility of women of childbearing age with tumors.
[0004] Technical solution: A specific targeting peptide CIBB composition, which comprises CIBB-1 shown in SEQ ID NO.1 and CIBB-2 shown in SEQ ID NO.2.
[0005] The CIBB-1 is encoded by the nucleic acid sequence shown in SEQ ID NO.3.
[0006] The CIBB-2 is encoded by the nucleic acid sequence shown in SEQ ID NO.4.
[0007] Application of a specific targeting peptide CIBB composition in the preparation of a drug for specifically reducing tumor damage to the ovary.
[0008] A drug for specifically reducing tumor damage to the ovary, comprising CIBB-1 shown in SEQ ID NO.1 and CIBB-2 shown in SEQ ID NO.2 as active ingredients.
[0009] A drug for specifically reducing tumor damage to the ovary, comprising CIBB-1 encoded by the nucleic acid sequence shown in SEQ ID NO.3 and CIBB-2 encoded by the nucleic acid sequence shown in SEQ ID NO.4 as effective ingredients.
[0010] The above-mentioned medicine further comprises a pharmaceutically acceptable carrier or excipient.
[0011] 1. For women of childbearing age with tumors, CIBB can be taken orally, by infusion or by intramuscular injection to protect ovarian function while suppressing tumors with traditional tumor treatments (radiotherapy, chemotherapy, etc.) or tumor immunotherapy (PD-1, CTAL4, WCV, etc.). The medication is taken once a day, 1 mg / kg. The course of treatment can be consistent with the tumor treatment.
[0012] 2. Since the TAT sequence in the CIBB polypeptide has the function of passing through the cell membrane, CIBB can also be added to cosmetics and skin care products for daily use, absorbed through the skin and finally enter the ovaries of women of childbearing age with tumors.
[0013] 3. Add it to health supplements.
[0014] 4. The above schemes are used in combination.
[0015] Beneficial effects: The polypeptide composition CIBB of the present invention can protect the ovarian function of women suffering from tumors from tumor damage.
[0016] 1. Since CIBB specifically blocks the binding of CXCL10 to the ovarian receptor IL18R1, CIBB does not affect the binding of other factors such as IL18 to IL18R1, and therefore does not interfere with the normal physiological functions of other inflammatory factors in the ovary;
[0017] 2. Since CIBB does not target tumor-associated receptors, it does not affect other tumor-suppressing therapies;
[0018] 3. As a peptide drug, CIBB has significant advantages over inhibitors, such as high specificity, high efficiency, high safety, low immunogenicity, high membrane permeability and low cost;
[0019] 4. CIBB can be used in combination with a variety of tumor treatment regimens to ensure the ovarian function and fertility of women of childbearing age with tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 . Heterotopic transplanted tumors reduce ovarian function;
[0021] A and B. Heterotopic transplantation of mouse tumor cells (MCA205) significantly reduced ovarian weight. C. The number of follicles at each stage was significantly reduced in B6 mice transplanted with MCA205. D and E. Blot and quantification showed that the level of anti-Müllerian hormone (AMH), an indicator of ovarian reserve function, was reduced in the ovaries of tumor-bearing mice. FI. Immunofluorescence staining of ovarian paraffin sections showed that the cell proliferation marker PCNA signal (F and G) was significantly reduced, while the apoptosis marker TUNEL signal was significantly increased in the ovaries of tumor-bearing mice. PCNA or TUNEL is green, and DNA is blue. The scale bar in A is 1 mm; the scale bars in F and H are 100 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ***: P < 0.0001.
[0022] Figure 2 .WCV treatment can protect ovarian function, while PD-1 antibody treatment cannot;
[0023] A. Schematic diagram of the specific time of different treatments (WCA, MCA205, PD-1antibody) of mice. Whole cancer cell vaccine (WCV, MTA-treated MCA205 tumor cells) was injected subcutaneously on day -12; MCA05 tumor cells were injected subcutaneously on day 0, and anti-PD-1 antibody was injected intravenously on days 4, 7, and 10. B. We set up 4 groups: CTR group (control group), normal B6 mice injected with PBS only; M(MCA205) group, normal B6 mice injected subcutaneously with MCA205 cells; VM(WCV+MCA205) group, normal B6 mice treated with WCV+MCA205 cells; PM(PD-1 antibody+MCA05) group, normal B6 mice treated with anti-PD-1 antibody+MCA205 cells. Tumor size measurements at multiple time points (days 3, 5, 7, 9, and 11) showed that tumor growth in the VM and PM groups was significantly slower than that in the M group, and tumor growth in the VM group was often even slower than that in the PM group. C. Tumor size measurement at the end of modeling showed that the tumor size of the VM and PM groups was significantly smaller than that of the M group, and the tumor size of the VM group was often even smaller than that of the PM group. D and E. Quantification showed that the number of ovulated oocytes in the M and PM groups was significantly lower than that in the CTR and VM groups. FH. In vitro maturation and quantification showed that there was no significant difference in the germinal vesicle breakdown (GVBD) rate among the four groups, but the MII rate was the lowest in the M group; no significant difference was observed between the CTR and VM groups, but the MII rate in the VM group was often higher than that in the PM group. IM. Follicle counting after H&E staining showed that the number of primordial follicles (PMF), secondary follicles (SF), and antral follicles (AF) in the M group was significantly reduced; anti-PD-1 antibody treatment did not show a rescue effect in the PM group, while WCV treatment significantly reversed the reduction in these numbers in the VM group. The scale bar in D is 100μm, the scale bar in F is 200μm, and the scale bar in I is 1mm. *: P<0.05; **: P<0.01; ***: P<0.001; ***: P<0.0001.
[0024] Figure 3 CXCL10 is the primary factor in impaired ovarian function under tumor invasion conditions;
[0025] A. RNA sequencing heat map shows that there are 435 differentially expressed genes (DEGs) between the CTR group and the M group at a threshold of |log2(M / CTR)|≥1. The expression profile of the VM group is very close to that of the CTR group, while the expression profile of the PM group is only slightly close to that of the CTR group. B. Three of the top 10 KEGG pathways of the DEGs are related to inflammation (red boxes). C. Plasma cytokine levels detected by cytokine microarray showed that among these cytokines, CXCL10 was the most upregulated in the M group (red dot rectangle); in the VM group, WCV treatment reduced CXCL10 levels to near control levels, while PD-1 antibody treatment had no effect on CXCL10 levels in the PM group. DG. Blot and quantification verified that CXCL10 was significantly increased in the plasma (D and E) and ovaries (F and G) of the M group; in the VM group, WCV treatment significantly reduced CXCL10 levels to near control levels, while in the PM group, PD-1 antibody treatment had no rescue effect. HK. Immunofluorescence and quantification showed that treatment of cultured ovaries with recombinant CXCL10 protein resulted in decreased proliferation (indicated by PCNA, H and I) and increased double-strand breaks (DSBs) (indicated by γH2AX, J and K), whereas combined treatment with anti-CXCL10 antibody restored the levels of PCNA and γH2AX to near the levels of the CTR group. Green is PCNA or γH2AX, and blue is DNA. Scale bars in H and J are 100 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ***: P < 0.0001.
[0026] Figure 4 IL18R1 is the dominant CXCL10 receptor in the ovary;
[0027] A. Purified GST-CXCL10 protein was immobilized on glutathione agarose beads and then incubated with ovarian lysates to identify potential CXCL10 interacting proteins in the ovary. IL18R1 was the only membrane receptor protein identified. B. pcDNA3.1-IL18R1-EGFP-strepII and pcDNA3.1-CXCL10-TagRFP-Flag plasmids were co-transfected into MCA205 cells followed by co-immunoprecipitation (Co-IP), showing the interaction between IL18R1 and CXCL10 in vivo. C. In vitro pull-down assays showed that CXCL10 coupled to glutathione agarose beads pulled down increasing amounts of reconstituted IL18R1 when increasing amounts of recombinant IL18R1 protein were added to the reaction. D and E. Blot and quantification showed that IL18R1 / CXCR3 was 2-fold higher in the ovary than in the tumor. F. Immunofluorescence showed that when recombinant StrepII-tagged CXCL10 protein was added to the culture medium containing oocytes and granulosa cells (GC), CXCL10 and IL18R1 were co-localized on the membrane. CXCL10 is red, IL18R1 is green, and DNA is blue. F scale bar is 20 μm. *: P < 0.05.
[0028] Figure 5 .WCV treatment reduces tumor-induced fibrosis via the CXCL10→IL18R1→COL1A1 pathway;
[0029] A and B. Masson staining and quantification showed that fibrosis (expressed as a percentage of the collagen fraction) was significantly increased in the M group; in the VM group, WCV treatment significantly reduced the fibrosis level to near the control level; while in the PM group, PD-1 antibody treatment had no significant rescue effect. C and D. RT-PCR and quantification showed that the mRNA level of Col1a1, encoding the collagen α1(I) chain, was significantly increased in the M group; in the VM group, WCV treatment significantly reduced the Col1a1 level to near the control level, while in the PM group, PD-1 antibody treatment had no significant rescue effect. EH. Blot and quantification showed that COL1A1 and its upstream regulators p-JNK and pc-JUN were significantly increased in the M group; in the VM group, WCV treatment significantly reduced these three proteins to near the control level; while in the PM group, PD-1 antibody treatment had no significant rescue effect. IK. Blot and quantification showed that in cultured ovaries, recombinant CXCL10 significantly increased p-JNK and COL1A1 levels, while anti-IL18R1 antibody co-treatment significantly reduced p-JNK and COL1A1 levels to close to the control group. L and M. Masson staining and quantification showed that in cultured ovaries, recombinant CXCL10 significantly increased fibrosis levels, while anti-IL18R1 antibody co-treatment significantly reduced fibrosis levels to close to the control group. N. Model. CXCL10 binds to the membrane receptor IL18R1 of oocytes and GCs, subsequently activating p-JNK and p-JUN, and ultimately promoting Col1a1 transcription and ovarian fibrosis. Scale bars in A and L are 50 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ***: P < 0.0001.
[0030] Figure 6 .WCV treatment reduced tumor-induced primordial follicle reduction via the CXCL10→IL18R1→AKT pathway;
[0031] A and B. Immunohistochemistry on paraffin sections of ovaries showed a significant increase in nuclear p-FOXO3A (arrows), indicating PMF activation, in the M group; in the VM group, WCV treatment significantly reduced nuclear p-FOXO3A levels to near control levels, while in the PM group, PD-1 antibody treatment had no significant rescue effect. CE. Blot and quantification showed that p-FOXO3A and its upstream regulator p-AKT were significantly increased in the M group; in the VM group, WCV treatment significantly reduced the levels of these two proteins to near control; while in the PM group, PD-1 antibody treatment had no significant rescue effect. FH. Blot and quantification showed that in cultured ovaries, recombinant CXCL10 significantly increased p-FOXO3A and p-AKT levels, while IL18R1 antibody treatment significantly reduced p-FOXO3A and p-AKT levels to near control. I and J. Immunohistochemistry and quantification of ovarian paraffin sections showed that recombinant CXCL10 significantly increased nuclear p-FOXO3A intensity in PMFs in cultured ovaries, whereas anti-IL18R1 antibody treatment significantly reduced p-FOXO3A-levels to near control. K. Model. CXCL10 binds to the membrane receptor IL18R1 of oocytes and GCs, subsequently activating p-AKT and p-FOXO3A, and ultimately promoting transcription of PMF-activated genes. Scale bars in A and I are 100 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.0001.
[0032] Figure 7 .WCV treatment reduced tumor-induced inflammation via the CXCL10→IL18R1→NFκB pathway;
[0033] AC. Blot and quantification showed that the levels of p-P65 and IFNγ in the M group were significantly increased; in the VM group, WCV treatment significantly reduced the levels of both to close to the control; while in the PM group, PD-1 antibody treatment had no significant rescue effect. DF. Blot and quantification showed that in the ovaries cultured in vitro, recombinant CXCL10 significantly increased the levels of p-P65 and IFNγ, while the combined treatment with IL18R1 antibody significantly reduced the levels of p-P65 and IFNγ to close to the control. G and H. Immunofluorescence and quantification showed that in the ovaries cultured in vitro, recombinant CXCL10 treatment significantly increased the number of INOS (a marker of proinflammatory M1 macrophages), while the combined treatment with IL18R1 antibody significantly reduced the number of INOS signal points to close to the control. INOS is green and DAPI is blue. I and J. Immunofluorescence and quantification showed that in cultured ovaries, recombinant CXCL10 treatment significantly reduced the number of CD206 (a marker of anti-inflammatory M2 macrophages), while IL18R1 antibody co-treatment significantly increased the number of CD206 signal points to close to the control. CD206 is green and DAPI is blue. K. Model. CXCL10 binds to the membrane receptor IL18R1 on oocytes and GCs, subsequently activates p-p65, and ultimately promotes the transcription of Ifng. Scale bars in G and I are 100 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.001.
[0034] Figure 8 CXCL10 antibody injection rescued tumor-induced ovarian function decline;
[0035] AE.Hematoxylin-eosin (HE) staining and follicle counting showed that the number of follicles at each stage was significantly reduced in the tumor-bearing mice of the M (MCA205) group, while in the CM (CXCL10 antibody plus MCA205 tumor) group, CXCL10 antibody treatment significantly increased the number of follicles at each stage to close to the control group. FI.Blot and quantification showed that the levels of p-JNK, pc-JUN, and COL1A1 were significantly increased in the ovaries of the M group, while in the CM group, CXCL10 antibody treatment significantly reduced the levels of these three to close to the control. J and K.Masson staining and quantification showed that ovarian fibrosis was significantly increased in the M group; CXCL10 antibody treatment significantly reduced the fibrosis level in the CM group to close to the control. LN.Blot and quantification showed that the levels of p-AKT and p-FOXO3A were significantly increased in the ovaries of the M group, while in the CM group, CXCL10 antibody treatment significantly reduced the levels of both to close to the control. O and P. Immunohistochemistry and quantification on ovarian paraffin sections showed that the intensity of nuclear p-FOXO3A in primordial follicles in the M group was significantly increased, while CXCL10 antibody treatment significantly reduced the intensity of p-FOXO3A in the CM group to close to the control. QS. Blot and quantification showed that the levels of p-P65 and IFNγ were significantly increased in the ovaries of the M group, while CXCL10 antibody treatment significantly reduced their levels to close to the control in the CM group. T and U. Immunofluorescence and quantification showed that the number of signal points of INOS (a marker of pro-inflammatory M1 macrophages) in the M group was significantly increased, while CXCL10 antibody treatment significantly reduced the intensity of p-FOXO3A in the CM group to close to the control. INOS is green and DAPI is blue. V and W. Immunofluorescence and quantification showed that the number of signal points of CD206 (a marker of anti-inflammatory M2 macrophages) in the M group was significantly reduced, while CXCL10 antibody treatment significantly increased the intensity of p-FOXO3A in the CM group to close to the control. CD206 is green and DAPI is blue. The scale bar in A is 1 mm; the scale bar in J is 200 μm; the scale bar in O is 100 μm; the scale bars in T and V are 100 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ***: P < 0.0001.
[0036] Fig. 9 .Injection of recombinant CXCL10-IL18R1 interface peptide rescued the decline in ovarian function induced by tumor invasion;
[0037] A and B. Protein-protein interaction predictions by AlphaFold show that two interaction models have the highest scores. In model 1 (A), 74-82AA of CXCL10 fits tightly with 245-306AA of IL18R1; in model 2 (right), 45-67AA of CXCL10 fits tightly with 243-297AA of IL18R1. We fused Flag (DYKDDDDK) and TAT (CYGRKKRRQRRR) to these two peptides. We mixed these two peptides together and used them as competitive peptides to inhibit the binding of CXCL10 to IL18R1. We named the combination of these peptides CIBB (CXCL10-IL18R1 binding blocker). C. Model: CIBB competes with CXCL10 for binding to IL18R1, thereby reversing the downstream signal induced by CXCL10. D and E. Immunofluorescence and quantification showed that when oocytes were treated with recombinant CXCL10 alone, a portion of CXCL10 could be internalized into the oocyte cytoplasm; however, when oocytes were co-treated with CXCL10 and CIBB, the internalization of CXCL10 was significantly reduced. CXCL10 (red) was detected with anti-CXCL10 antibody, CIBB (green) was detected by anti-Flag antibody, and DNA was blue. The ovarian weight of the F and GM groups was significantly reduced, while CIBB treatment increased the ovarian weight of the CI-M group (MCA205 tumor + CIBB treatment) to a level close to that of the control group. HK. Blot and quantification showed that in the ovaries of the M group, the levels of p-JNK, pc-JUN, and COL1A1 were significantly increased, while in the CI-M group, CIBB treatment significantly reduced the levels of these three to close to the control. L and M. Masson staining and quantification showed that the fibrosis of the ovaries of the M group was significantly increased, while in the CI-M group, CIBB treatment significantly reduced the fibrosis level to close to the control. NP.Blot and quantification showed that the levels of p-AKT and p-FOXO3A in the ovaries of the M group increased significantly, while CIBB treatment significantly reduced the levels of these two in the CI-M group to close to the control. Q and R. Immunohistochemistry and quantification of ovarian paraffin sections showed that the intensity of nuclear p-FOXO3A in PMFs increased significantly in the M group, while CIBB treatment significantly reduced the intensity of p-FOXO3A to close to the control in the CI-M group. SU.Blot and quantification showed that the levels of p-P65 and IFNγ in the ovaries of the M group increased significantly, while CIBB treatment significantly reduced the levels of these two in the CI-M group to close to the control. V and W. Immunofluorescence and quantification showed that the number of signal points of INOS, a marker of proinflammatory M1 macrophages, increased significantly in the M group, while CIBB treatment reduced the number of signal points of INOS to close to the control in the CI-M group. INOS is green and DAPI is blue.X and Y. Immunofluorescence and quantification showed that the number of signal points of CD206, a marker of anti-inflammatory M2 macrophages, was significantly reduced in the M group, while CIBB treatment significantly increased the number of CD206 signal points in the CI-M group to a level close to that of the control group. CD206 is green and DAPI is blue. The scale bar in D is 20 μm; the scale bar in L is 200 μm; the scale bar in Q is 100 μm; the scale bars in V and X are 100 μm. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ***: P < 0.0001.
[0038] Fig.10 .Injection of recombinant CXCL10-IL18R1 interface peptide rescued the decline in ovarian function induced by tumor invasion;
[0039] Under tumor invasion, the level of CXCL10 in the blood circulation increases significantly and can be transported to the ovary through the blood circulation. WCV treatment can inhibit tumor growth and reduce the concentration of CXCL10. Anti-CXCL10 antibodies can directly bind to CXCL10 to inhibit its function; similarly, anti-IL18R1 antibodies can directly bind to IL18R1 to inhibit the binding of CXCL10-IL18R1. CIBB can compete with CXCL10 for binding to IL18R1, thereby blocking the three major downstream signaling pathways of CXCL10→IL18R1: overactivation of PMFs caused by AKT and FOXO3A phosphorylation; increased ovarian inflammation caused by P65 phosphorylation promoting IFNγ transcription; and ovarian fibrosis caused by JNK and c-JUN phosphorylation promoting COL1A1 transcription.
[0040] Fig.11 Mass spectrometric identification of CIBB-1;
[0041] Fig.12 Mass spectrometry identification of CIBB-2. DETAILED DESCRIPTION
[0042] Example 1
[0043] Scenario 1:
[0044] Currently, CIBB-1 and CIBB-2 are synthesized by the company, and the products are identified by mass spectrometry. Fig.11 and Fig.12 shown.
[0045] Scenario 2:
[0046] The DNA sequences corresponding to CIBB-1 and CIBB-2 were cloned into pGEX-6P2 and transformed into BL21-DE-Plys Escherichia coli for prokaryotic protein expression. A small amount of bacteria was added to 100 mL LB culture medium to proliferate. The bacterial solution was added to 4 L LB+ culture medium at a volume ratio of 1:50 and cultured in a shaker at 200 RPM and 37°C until OD 600 =0.6, 0.1 mmol / L IPTG was added, and induced at 16°C, 200 RPM overnight for 16 hours. The cells were collected by centrifugation at 3500 rpm for 10 minutes at 4°C, washed with ice-cold PBS at pH 7.3, and lysed in 25 mL of lysis buffer (PBS, pH 7.3, 1 mM DTT, 1 mM PMSF, 1% TritonX-100, 1:100 InStab TM Protease inhibitor cocktail (Yeasen), 1:100 InStab TM Lyse in a phosphatase inhibitor cocktail (Yeasen). After standing on ice for 15 minutes, the cells were broken with a high-pressure crusher and the supernatant (containing the fusion protein) was collected by centrifugation at 16000RPM at 4°C. The fusion protein was captured with 1mL glutathione agarose resin at 4°C for 30 minutes. Next, the resin bound to the GST fusion polypeptide was transferred to a 10mL chromatographic column, and the resin was washed three times with 20mL of washing buffer. Finally, the GST fusion polypeptide was eluted with elution buffer (1x PBS, 1mM MgSO4, 0.5mM DTT, 10mM Glutathione, pH 7.4). To cut off the GST tag, the GST fusion polypeptide was transferred into the PreScission column by centrifugation using a size-exclusion spin column. TM Protease digestion buffer (50mM Tris, pH 8.0, 0.5mM EDTA, 1mM DTT), PreScission TM The ratio of protease enzyme to GST fusion polypeptide was 1:25-1:100 U / μg fusion polypeptide, and the enzyme digestion was carried out overnight at 4°C. Finally, CIBB-1 and CIBB-2 polypeptides were recovered, and the concentration of the polypeptides was determined by comparing the intensity of the polypeptides with the standard BSA on SDS-PAGE gel.
[0047] Example 2
[0048] Since CXCL10 is the main inflammatory factor affecting the ovaries by tumors, and IL18R1 is the main receptor of CXCL10 on the ovaries, we speculated that preventing the binding of CXCL10 and IL18R1 may effectively protect the ovaries from tumor damage. We used AlphaFold to predict two regions where CXCL10 and IL18R1 fit closely together, and fused Flag (DYKDDDDK) and TAT (CYGRKKRRQRRR) to these two peptides, naming them CIBB-1 (CXCL10-IL18R1 binding blocker) and CIBB-2 ( Fig. 9 A and B). We mixed these two peptides to inhibit the binding of CXCL10 to IL18R1 and named it CIBB ( Fig. 9 C). CIBB was dissolved in 10% DMSO (Sigma) diluted with sterile ultrapure water. The concentration of the concentrate was 5 mg / ml. The concentrate was diluted with 0.9% sodium chloride solution to a final concentration of 0.5 mg / ml and injected into the peritoneal cavity of experimental mice at a dose of 6 mg / kg. The TAT sequence CYGRKKRRQRRR was used as a control peptide and injected into the control mice at a dose of 6 mg / kg. CIBB can significantly prevent CXCL10 from entering the oocyte ( Fig. 9 D and E). Mouse fibrosarcoma cells MCA205 were transplanted subcutaneously into normal B6 female mice to construct a homologous heterotopic fibrosarcoma model. It was found that fibrosarcoma (M group) significantly reduced the ovarian weight, while CIBB treatment (CI-M group) significantly restored the ovarian weight ( Fig. 9 FG). Blot and quantification showed that fibrosarcoma (M group) significantly increased the levels of p-JNK, pc-JUN and COL1A1 in the ovary, while CIBB treatment (CI-M group) significantly restored the levels of these three proteins ( Fig. 9 HM); fibrosarcoma (M group) significantly increased the levels of p-AKT and p-FOXO3A, while CIBB treatment (CI-M group) significantly restored the levels of both ( Fig. 9 NR); in addition, fibrosarcoma (M group) significantly increased the levels of p-P65 and IFNγ, while CIBB treatment (CI-M group) significantly restored these two levels ( Fig. 9 SY). The above results show that CIBB can effectively protect the ovaries from damage caused by tumor invasion (fibrosis, inflammation and excessive activation of follicles).
Claims
1. A specific targeting peptide CIBB composition, characterized in that: The composition comprises CIBB-1 shown in SEQ ID NO.1 and CIBB-2 shown in SEQ ID NO.
2.
2. The specific targeting peptide CIBB composition according to claim 1, characterized in that: The CIBB-1 is encoded by the nucleic acid sequence shown in SEQ ID NO.
3.
3. The specific targeting peptide CIBB composition according to claim 1, characterized in that: The CIBB-2 is encoded by the nucleic acid sequence shown in SEQ ID NO.
4.
4. Application of the specific targeting peptide CIBB composition in the preparation of drugs that specifically reduce tumor damage to the ovaries.
5. A drug that specifically reduces tumor damage to the ovary, characterized in that: The invention contains CIBB-1 represented by SEQ ID NO. 1 and CIBB-2 represented by SEQ ID NO. 2 as active ingredients.
6. A drug that specifically reduces tumor damage to the ovary, characterized in that: It contains CIBB-1 encoded by the nucleic acid sequence shown in SEQ ID NO.3 and CIBB-2 encoded by the nucleic acid sequence shown in SEQ ID NO.4 as active ingredients.
7. The drug for specifically reducing tumor damage to the ovary according to claim 5 or 6, characterized in that: The medicament also contains a pharmaceutically acceptable carrier or excipient.
